Universal Peace Federation: 70 Years After the Korean War, UPF Holds Online Summit for Peace and Reconciliation
The Rally of Hope, the third organized by UPF, is expected to draw much international participation this weekend. This rally, produced in Korea, will focus mainly on the Korean peninsula, seventy years after the outbreak of the Korean war (1950-53). UPF is an NGO in general consultative status with the Economic and Social Council of the United Nations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005660/en/
The Little Angels’ performance to thank the countries that came to South Korea’s aid in commemoration of the 70th anniversary of the outbreak of the Korean War (Photo: Business Wire)
Remembering yesterday’s war heroes; highlighting today’s peacemakers
In addition to featuring prominent global leaders, the renowned Little Angels Folk Ballet of Korea will perform a special tribute in honor of veterans of the Korean War.
Dr. Hak Ja Han Moon, the co-founder of UPF, will be keynote speaker. Her husband, the late Reverend Moon, was liberated by UN forces from the North Korean death camp of Heungnam. In her memoirs, Mother of Peace, Mrs. Moon explains how she escaped death several times during this conflict.
Further speakers include current and former heads of state and government whose countries were part of the United Nations forces in the Korean War: Sahle-Work Zewde, president of Ethiopia, the only current female head of State in Africa; Yves Leterme, Prime Minister of Belgium (2009-2011); Stephen Harper Prime Minister of Canada (2006-2015), now chairman of the International Democrat Union.
Other speakers include current heads of state whose countries have overcome domestic tensions and progressed toward national reconciliation: Salva Kiir, President of South Sudan, who recently invited the UPF chairman to attend the signing of the Juba peace agreement; Uhuru Kenyatta, President of Kenya and Mahinda Rajapaska, Prime Minister of Sri Lanka.
Mr. Jacques Marion, president of UPF Europe-Middle East, remarked that the Rally of Hope sets a strong signal for a peaceful unification. The interfaith prayer by religious leaders, the presence of Veterans of the Korean war representing the conflicting armies, will testify and sound an appeal for reconciliation on the divided peninsula, he said.
UPF states on its website that a main objective is the “peaceful reunification of the Korean peninsula and harmonious relations among the nations of Northeast Asia.” Directed towards this goal, UPF strives to realize the vision of a global democratic society, driven by the free-market and centered on family-based universal values.
This rally will be a dazzling display of digital technology from the land of K‑pop. A live internet audience of millions will be joined by an interactive audience using various social media apps.
Rally of Hope - Live Broadcast:
Date: November 22, 2020, 1:30 AM - 3:30 AM CET
Participants: VIPs & guests from all over the world (register at: rallyofhope.eu)
Highlights of the Rally (Online):
November 22, 2020, 6:00 PM - 7:00 PM CET
Participants: VIPs & guests from all over Europe & Middle East
Public registration for the rally (live or highlights) at: rallyofhope.eu
Media direct live streaming will use: peacelink.live
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005660/en/
Contact information
Peter Zoehrer, UPF Media Relations - Europe & Middle East
Phone: +43 (0) 6645238794
media@europe.upf.org
Websites: UPF.ORG & EUME.UPF.ORG
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom